{"url_path":"/sec/kapa/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ** **Financial Statement and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-033289-index.html","accession_number":"0001493152-26-033289","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-033289-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":83,"has_tables":true,"body_markdown":"**Item 9.01.** **Financial Statement and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n99.1\n \n[Press Release dated July 15, 2026](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nKAIROS\nPHARMA, LTD.\n\nDated:\nJuly 15, 2026\n \n \n\n \nBy:\n*/s/\nJohn S. Yu*\n\n \nName:\n\nJohn\nS. Yu\n\n \nTitle:\nChief\nExecutive Officer\n\n \n\n3"}